Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Feb 15;121(4):556-61.
doi: 10.1002/cncr.29085. Epub 2014 Oct 21.

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

Jean-Pierre Issa  1 , Guillermo Garcia-Manero, Xuelin Huang, Jorge Cortes, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Mark Brandt, Sherry Pierce, Hagop M Kantarjian
Affiliations
Clinical Trial

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

Jean-Pierre Issa et al. Cancer. .

Abstract

Background: Hypomethylating agents have demonstrated activity in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Preclinical and single-arm trials have suggested that adding histone deacetylase (HDAC) inhibitors may synergize the epigenetic modulation of hypomethylating agents and improve treatment results.

Methods: The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML.

Results: Patients with higher risk MDS or with AML aged ≥60 years were eligible. Patients were randomized in a Bayesian response-adaptive design to receive intravenous decitabine 20 mg/m(2) daily for 5 days or decitabine plus oral valproic acid 50 mg/kg daily for 7 days. Courses were repeated every 4 to 6 weeks. A maximum of 150 patients were to be treated. In total, 149 patients were treated on study, including 87 patients with MDS and 62 patients with AML. The median patient age was 69 years (range, 20-89 years; 42% of patients were aged ≥70 years). Overall, 34% of patients achieved complete remission, and 55% had an objective response. The median survival was 11.9 months, and the estimated 2-year survival rate was 27%. Outcome was not different with the addition of valproic acid to decitabine versus decitabine alone in relation to the rates of complete remission, overall response, or survival. Subset analyses did not demonstrate a benefit within the MDS or AML categories. Toxicities-particularly neurotoxicities-were higher with the combination arm.

Conclusions: Adding valproic acid to decitabine was not associated with improved outcome in the treatment of patients with MDS or elderly patients with AML. Future therapies may consider combining hypomethylating agents with better HDAC inhibitors and using different schedules.

Keywords: acute myelogenous leukemia; decitabine; histone deacetylase; hypomethylating agents; inhibitors; myelodysplastic syndrome; trials; valproic acid.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None

Figures

Figure 1
Figure 1
Survival by treatment with decitabine (DAC) ± valproic acid (VPA), overall (A), in MDS (B), and AML (C).
Figure 1
Figure 1
Survival by treatment with decitabine (DAC) ± valproic acid (VPA), overall (A), in MDS (B), and AML (C).
See this image and copyright information in PMC

References

    1. Faderl S, Kantarjian H. Myelodysplastic Syndromes. In: DeVita V, Lawrence T, Rosenberg S, editors. Cancer Principles and Practice of Oncology. 9th. Lippincott Williams and Wilkins; Philadelphia, PA: 2011. pp. 1988–96.
    1. Silverman L. The Myelodysplastic Syndrome. In: Hong WK, Blast RC, Hait WN, et al., editors. Cancer Medicine. 8th. Shelton, CT: People's Medical Publishing House-USA; 2010. pp. 1544–58.
    1. Foran JM, Sekeres MA. Myelodysplastic Syndromes. In: Aberloff M, Armitage J, Niederhuber J, Kastan M, McKenna W, editors. Abeloff's Clinical Oncology. 4th. Churchill Livingstone Elsevier; Philadelphia, PA: 2008. pp. 2235–2259.
    1. Greenberg P, Cox C, LeBeau MM, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:20792088. - PubMed
    1. Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65. - PMC - PubMed

Publication types

MeSH terms